Skip to main content
Kolinpharma logo

Kolinpharma — Investor Relations & Filings

Ticker · KIP ISIN · IT0005322950 LEI · 815600FC8F1A3BED2743 XMIL Manufacturing
Open in API
Filings indexed 222 across all filing types
Latest filing 2018-06-22 Capital/Financing Update
Country IT Italy
Listing XMIL KIP

About Kolinpharma

https://www.kolinpharma.com/index-en

Kolinpharma is a nutraceutical company established in 2013, specializing in the research and development of innovative products designed to improve well-being and quality of life. The company's core activities are centered on scientific research and product innovation, creating high-quality nutraceuticals. It operates an in-house R&D department and collaborates with leading universities for in-vitro and clinical studies. As a certified B Corporation, Kolinpharma adheres to high standards of social and environmental performance. The company distributes its proprietary branded products through a qualified network of medical-scientific representatives.

Recent filings

Filing Released Lang Actions
PRICE SENSITIVE-COMUNICATO STAMOA
Capital/Financing Update Classification · 1% confidence The document is a press release dated June 22, 2018, announcing that KOLINPHARMA has signed a factoring agreement (a financing activity) for up to 2 million Euros with Banca IFIS S.p.A. This action directly relates to the company's capital structure, fundraising, and liquidity management. Based on the definitions, this fits best under 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it describes a specific financing transaction.
2018-06-22 Italian
comunicato internal dealing
Director's Dealing Classification · 1% confidence The document is an official notification from KOLINPHARMA S.p.A. dated June 20, 2018. The 'Oggetto' (Subject) explicitly states 'comunicato internal dealing' (insider dealing communication). The template used is titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' This directly corresponds to the definition of Director's Dealing (insider trades). Therefore, the filing type is DIRS.
2018-06-20 Italian
COMUNICAZIONE INTERNAL DEALING
Director's Dealing Classification · 1% confidence The document is a formal notification titled 'Modello di notifica e di comunicazione al pubblico delle operazioni effettuate da persone che esercitano funzioni di amministrazione, di controllo o di direzione e da persone a loro strettamente associate' (Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them). This directly corresponds to the reporting requirements for insider trading or director's dealings, which is covered by the 'Director's Dealing' category. The key indicators are: 1. Subject ('Oggetto'): 'COMUNICAZIONE INTERNAL DEALING'. 2. Template Title: Explicitly mentions transactions by persons discharging managerial responsibilities (insiders). 3. Company: KOLINPHARMA S.p.A. 4. Filing Date: 05 Giugno 2018. This matches the definition for Director's Dealing (DIRS).
2018-06-05 Italian
PRICE SINSITIVE:COMUNICATO STAMPA
Regulatory Filings Classification · 1% confidence The document is titled 'Informazione Regolamentata' (Regulated Information) and the 'Oggetto' (Subject) is 'PRICE SENSITIVE: COMUNICATO STAMPA' (Price Sensitive: Press Release). The content discusses positive operational updates (46% increase in medical prescriptions in Q1 2018), expansion of the sales force, and the initiation of an international division. This is a typical announcement of material, non-public information intended to inform the market immediately about significant business developments that could affect the stock price. Since it is a press release announcing operational results and strategic moves, and not a full periodic report (like 10-K or IR), it best fits the 'Earnings Release' (ER) category if it were purely financial highlights, or more generally, a 'Regulatory Filing' (RNS) as it is a general price-sensitive announcement. Given the focus on operational growth and management changes rather than just summarized quarterly figures, and the explicit mention of 'COMUNICATO STAMPA', it functions as an immediate market disclosure. Since 'ER' is defined as the *initial announcement of periodical financial results (key highlights only)*, and this document contains operational metrics (prescriptions) and strategic news (international expansion), it leans towards a general regulatory disclosure. However, in many contexts, operational updates released via press release are classified as Earnings Releases or similar disclosures. Given the strong operational/financial update nature, ER is a strong candidate, but RNS is the safest fallback for general price-sensitive press releases not explicitly fitting other detailed report types. Since it contains specific Q1 operational metrics and strategic updates, it is more specific than a generic RNS. I will classify it as an Earnings Release (ER) as it provides key performance indicators for the first quarter, even if not a full financial statement.
2018-05-25 Italian
COMUNICATO INTERNAL DEALING
Director's Dealing Classification · 1% confidence The document is titled 'COMUNICATO INTERNAL DEALING' (Internal Dealing Communication) and uses a standardized template for 'notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' This directly corresponds to reporting insider trades or director dealings. The filing type code for Director's Dealing is DIRS.
2018-05-23 Italian
COMINICATO STAMPA ASSEMBLEA DEGLI AZIONISTI APPROVAZIONE BILANCIO DEL 08-05-2018
AGM Information Classification · 1% confidence The document is titled 'COMINICATO STAMPA ASSEMBLEA DEGLI AZIONISTI APPROVAZIONE BILANCIO DEL 08-05-2018' (Press Release Shareholders' Meeting Approval of the 2017 Financial Statements). It details the approval of the 2017 Financial Statements by the Shareholders' Assembly and provides key financial highlights (Revenues, EBITDA, Net Result, PFN) for the year ended December 31, 2017. This content structure—a press release summarizing the results of a formal meeting where the annual accounts were approved—is characteristic of an Earnings Release (ER) or, more specifically, a document announcing the outcome of the AGM regarding financial results. Since the core content is the summary of the approved annual financial results, it aligns closely with an Earnings Release (ER) which typically precedes or accompanies the full 10-K filing, or an Interim Report (IR) if it were for a shorter period. However, the approval of the *annual* financial statements by the assembly strongly suggests this is the primary announcement of the annual results. Given the options, 'ER' (Earnings Release) is the best fit for a press release summarizing key annual financial performance metrics approved at the AGM, even though the AGM itself is mentioned. If the document were the full financial statements, it would be 10-K. Since it is a press release summarizing the approval of the annual accounts, ER is appropriate. The document length (6042 chars) is substantial enough to contain key figures, moving it beyond a simple RPA.
2018-05-08 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.